A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia

Inclusion Criteria: * Diagnosis of chronic schizophrenia that is clinically stable * Body mass index (BMI) between 18.5 and 35.0 kg/m2, inclusive * Stable antipsychotic medication regimen for \>/= 2 months before Screening * Be willing and able to be confined to an inpatient clinical research unit for a total of 37 days during the course of the study Exclusion Criteria: * Aripiprazole used within 30 days before Screening * History of intolerance of or allergy or hypersensitivity to aripiprazole, its excipients, other antipsychotic agents, or INTRALIPID (including peanuts, soy, egg, or glycerol) * Current diagnosis of an Axis I disorder other than schizophrenia * History of seizure disorder or any condition associated with seizures * History of neuroleptic malignant syndrome (NMS) * Positive test result for HIV, hepatitis B surface antigen, or anti-hepatitis C antibodies * Received medication by IM injection within 30 days before Screening * Monoamine oxidase inhibitors (eg, phenelzine, tranylcypromine, selegiline) used within 30 days before Screening * DSM-IV-TR diagnosis of alcohol or substance dependence, with the exception of nicotine or caffeine dependence within 12 months before Screening * Donation of blood or blood components within 4 weeks before Screening